CANCER TREATMENT REVIEWS

Scope & Guideline

Exploring the forefront of therapeutic innovations.

Introduction

Welcome to your portal for understanding CANCER TREATMENT REVIEWS, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0305-7372
PublisherELSEVIER SCI LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1974 to 1991, from 1993 to 2024
AbbreviationCANCER TREAT REV / Cancer Treat. Rev.
Frequency10 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address125 London Wall, London EC2Y 5AS, ENGLAND

Aims and Scopes

CANCER TREATMENT REVIEWS focuses on the latest advancements in cancer treatment, providing comprehensive analyses and reviews of various therapeutic approaches. The journal aims to facilitate the understanding of complex cancer therapies through systematic reviews, meta-analyses, and consensus papers, thereby contributing to improved clinical practices in oncology.
  1. Comprehensive Reviews of Therapeutics:
    The journal publishes extensive reviews on various therapeutic modalities, including chemotherapy, immunotherapy, targeted therapy, and emerging treatments, ensuring that oncologists are updated on the latest evidence-based practices.
  2. Systematic Reviews and Meta-Analyses:
    A significant portion of the journal's content includes systematic reviews and meta-analyses that synthesize data from multiple studies, providing a clearer picture of treatment efficacy and safety across various cancer types.
  3. Focus on Precision Medicine:
    CANCER TREATMENT REVIEWS emphasizes precision medicine, exploring how genetic and molecular profiling can guide treatment decisions and improve patient outcomes in oncology.
  4. Interdisciplinary Approach:
    The journal promotes an interdisciplinary approach to cancer treatment, integrating insights from various fields such as surgery, radiology, and pharmacology to enhance the understanding and management of cancer.
  5. Emerging and Innovative Therapies:
    Regularly features discussions on innovative therapeutic strategies, including novel drug classes, combination therapies, and the role of technology in cancer treatment, thus highlighting cutting-edge research.
CANCER TREATMENT REVIEWS is at the forefront of exploring new and emerging themes in cancer treatment. The following areas have gained significant traction in recent publications, reflecting the journal's commitment to advancing the field of oncology.
  1. Immunotherapy and Combination Therapies:
    Recent publications increasingly focus on immunotherapy, especially its combination with other treatment modalities, highlighting its potential to enhance efficacy in various cancers.
  2. Targeted Therapies and Precision Oncology:
    There is a growing emphasis on targeted therapies, particularly those that exploit specific genetic mutations or tumor characteristics, which are becoming central to personalized cancer treatment strategies.
  3. Liquid Biopsy and Biomarker Development:
    Emerging themes include the use of liquid biopsies for early cancer detection and monitoring treatment response, along with the development of new biomarkers that guide therapy selection.
  4. Patient-Centered Care Approaches:
    The journal is increasingly addressing the importance of patient-centered care, focusing on the incorporation of patient-reported outcomes and shared decision-making in treatment planning.
  5. Management of Treatment-Related Toxicities:
    There is a rising trend in discussions about managing side effects and toxicities associated with cancer treatments, reflecting a holistic approach to patient care that prioritizes quality of life.

Declining or Waning

While CANCER TREATMENT REVIEWS continues to explore a broad spectrum of cancer therapies, certain themes appear to be declining in prominence. This reflects the evolving landscape of cancer treatment and the shift towards more personalized and targeted approaches.
  1. Traditional Chemotherapy:
    There is a noticeable decrease in reviews focused solely on traditional chemotherapy regimens, as the field increasingly shifts towards targeted therapies and immunotherapies that offer improved efficacy and reduced toxicity.
  2. Single-Agent Therapies:
    The frequency of publications centered on single-agent therapies is declining, as there is a growing emphasis on combination therapies that leverage synergistic effects to enhance treatment outcomes.
  3. Conventional Radiotherapy Techniques:
    While radiotherapy remains crucial, discussions surrounding conventional techniques are waning in favor of advanced modalities such as stereotactic body radiotherapy and biologically targeted radiotherapy.
  4. Generalized Treatment Protocols:
    The journal has seen a reduction in papers proposing generalized treatment protocols, as the focus shifts towards individualized treatment plans that cater to specific patient profiles and tumor characteristics.
  5. Outdated Biomarkers:
    There is less emphasis on older biomarkers that are no longer considered clinically relevant, with more attention being directed towards novel and clinically actionable biomarkers.

Similar Journals

Gaceta Mexicana de Oncologia

Innovative Findings, Accessible Solutions in Oncology.
Publisher: SOC MEXICANA ONCOLOGIA, A CISSN: 1665-9201Frequency: 6 issues/year

Gaceta Mexicana de Oncologia, published by the SOC MEXICANA ONCOLOGIA, A C, is a prominent Open Access journal that has contributed significantly to the field of oncology since its inception in 2002. With an ISSN of 1665-9201, this journal is dedicated to disseminating high-quality research pertaining to cancer studies, making it an essential resource for researchers, healthcare professionals, and students alike. Operating out of Spain, it serves as a platform for sharing innovative findings and clinical advancements in oncology. The journal's impact in the research community is reflected in its current rankings, placing it in the Q4 category for Cancer Research and Oncology fields. Despite its emerging status within the academic tiers, Gaceta Mexicana de Oncologia aims to enhance its presence in the scholarly domain, especially during its converged years from 2009 to 2024. The accessibility of its articles empowers a wider audience, fostering collaboration and knowledge-sharing necessary for combating cancer in diverse populations.

Nature Reviews Clinical Oncology

Pioneering Insights for Tomorrow's Treatments
Publisher: NATURE PORTFOLIOISSN: 1759-4774Frequency: 12 issues/year

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

Therapeutic Advances in Medical Oncology

Catalyzing collaboration for improved cancer outcomes.
Publisher: SAGE PUBLICATIONS LTDISSN: 1758-8340Frequency: 1 issue/year

Therapeutic Advances in Medical Oncology, an esteemed journal published by SAGE Publications Ltd, serves as a critical platform for disseminating high-quality research pertinent to the field of oncology. Indexed under the ISSN 1758-8340 and E-ISSN 1758-8359, this Open Access journal has made significant strides since its inception in 2009, attaining a commendable rank of #78 out of 404 in the Medicine - Oncology category of Scopus, placing it in the top 20th percentile of journals. With its category quartile of Q1 established in 2023, it underscores the journal’s commitment to advancing therapeutic approaches in oncology, making it an invaluable resource for researchers, clinicians, and students alike. Offering unrestricted access to pioneering studies since 2017, it aligns with the global movement towards open science, fostering collaboration and innovation among professionals striving to improve cancer treatment outcomes. By bridging the gap between research and clinical practice, Therapeutic Advances in Medical Oncology plays a vital role in shaping the future of cancer therapy.

Trends in Cancer

Transforming Cancer Research Through Scholarly Excellence
Publisher: CELL PRESSISSN: 2405-8025Frequency: 12 issues/year

Trends in Cancer is a leading journal published by CELL PRESS, dedicated to advancing the field of cancer research and oncology. Since its inception in 2015, the journal has rapidly gained a reputation for excellence, securing both Q1 rankings in Cancer Research and Oncology categories for 2023 and boasting impressive Scopus ranks—#13 out of 404 in Medicine Oncology and #9 out of 230 in Biochemistry, Genetics and Molecular Biology, thus placing it in the top 4% of its field. The journal aims to publish high-quality, innovative research that offers new insights into cancer biology and treatment strategies. With a commitment to scholarly rigor and a broad scope that encompasses molecular mechanisms to therapeutic approaches, Trends in Cancer serves as an essential resource for researchers, professionals, and students eager to stay informed about the latest developments in cancer science. Although it is not an open-access journal, its contributions are pivotal in shaping the future of cancer research.

LANCET ONCOLOGY

Leading the way in oncology research and clinical excellence.
Publisher: ELSEVIER SCIENCE INCISSN: 1470-2045Frequency: 12 issues/year

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.

Molecular and Clinical Oncology

Innovating cancer care through rigorous research.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Oncologie

Transforming cancer treatment through rigorous research.
Publisher: WALTER DE GRUYTER GMBHISSN: 1292-3818Frequency: 6 issues/year

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

ONCOLOGY

Empowering breakthroughs in oncology and patient care.
Publisher: KARGERISSN: 0030-2414Frequency: 12 issues/year

ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Elevating research in oncology and hematology.
Publisher: ELSEVIER SCIENCE INCISSN: 1040-8428Frequency: 12 issues/year

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, published by Elsevier Science Inc, stands at the forefront of the medical literature dedicated to advancing our understanding of cancer and blood disorders. With its ISSN 1040-8428 and E-ISSN 1879-0461, this prestigious journal boasts an impressive impact factor, reflecting its significance in the fields of Geriatrics, Hematology, and Oncology. Notably, it has achieved the distinction of being ranked in the top quartile (Q1) for these categories as of 2023, with Scopus rankings placing it in the 93rd percentile in Geriatrics and Gerontology, 87th in Oncology, and 85th in Hematology. Since its inception in 1983 and continuing until 2024, the journal serves as a critical resource for researchers, medical professionals, and students alike, aiming to publish high-quality, peer-reviewed articles that facilitate knowledge exchange and promote innovation in clinical practices and therapeutic strategies. While the journal is not open access, it remains widely accessible through various academic institutions, ensuring that vital research findings reach those who need them most.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Championing Excellence in Cancer Research and Clinical Practice.
Publisher: SPRINGERISSN: 0171-5216Frequency: 12 issues/year

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.